Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$291.91
+0.8%
$281.75
$253.30
$346.85
$157.02B0.512.82 million shs1.95 million shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$109.23
+1.1%
$106.07
$64.86
$119.96
$135.92B0.297.76 million shs7.21 million shs
GSK PLC Sponsored ADR stock logo
GSK
GSK
$37.92
-1.9%
$38.51
$31.72
$44.67
$77.68B0.524.91 million shs4.80 million shs
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$21.63
-1.1%
$19.47
$13.45
$44.42
$1.90B0.041.03 million shs228,021 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$764.87
-2.6%
$779.84
$677.09
$972.53
$724.66B0.43.65 million shs2.79 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$79.57
+0.3%
$78.89
$73.31
$134.63
$199.77B0.3812.94 million shs7.57 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$23.91
+0.1%
$23.22
$20.92
$31.54
$135.91B0.5741.17 million shs21.18 million shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
0.00%-2.58%+5.32%-8.36%-5.35%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.00%-3.61%-1.02%+0.86%+71.02%
GSK PLC Sponsored ADR stock logo
GSK
GSK
0.00%-9.04%+0.72%-1.45%-5.60%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
0.00%-1.89%+11.36%+18.87%-41.35%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%-3.37%+5.17%-6.57%-12.02%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.00%-3.03%+1.72%-15.17%-38.07%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%-3.92%+1.55%-8.89%-12.90%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amgen Inc. stock logo
AMGN
Amgen
4.4743 of 5 stars
2.24.03.33.93.62.50.6
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
4.9765 of 5 stars
2.45.04.24.13.92.53.1
GSK PLC Sponsored ADR stock logo
GSK
GSK
2.3355 of 5 stars
1.14.02.50.02.70.02.5
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
3.6246 of 5 stars
3.52.00.04.41.41.70.0
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.9494 of 5 stars
4.43.03.34.02.81.71.9
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
4.9962 of 5 stars
3.25.05.03.93.02.53.8
Pfizer Inc. stock logo
PFE
Pfizer
4.8525 of 5 stars
2.34.04.24.32.31.73.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.38
Hold$309.226.56% Upside
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.78
Moderate Buy$110.552.55% Upside
GSK PLC Sponsored ADR stock logo
GSK
GSK
2.27
Hold$37.38-2.26% Downside
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
2.93
Moderate Buy$54.27148.95% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.76
Moderate Buy$1,011.3733.16% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.43
Hold$109.1938.49% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.53
Moderate Buy$29.1722.27% Upside

Current Analyst Ratings Breakdown

Latest IDYA, LLY, PFE, AMGN, GILD, MRK, and GSK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/20/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$936.00 ➝ $936.00
6/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
6/3/2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
5/23/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/22/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$63.00 ➝ $66.00
5/21/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/20/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Cautious
5/20/2025
Amgen Inc. stock logo
AMGN
Amgen
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$288.00
5/16/2025
Amgen Inc. stock logo
AMGN
Amgen
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$329.00 ➝ $328.00
5/14/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$115.00 ➝ $84.00
5/8/2025
Amgen Inc. stock logo
AMGN
Amgen
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$33.42B4.67$30.42 per share9.54$10.93 per share26.55
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$28.75B4.66$6.86 per share15.72$15.44 per share6.98
GSK PLC Sponsored ADR stock logo
GSK
GSK
$40.10B1.95$5.52 per share6.93$8.07 per share4.74
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$7M272.76N/AN/A$12.25 per share1.78
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B15.98$13.77 per share55.15$15.03 per share50.53
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$64.17B3.09$9.41 per share8.38$18.33 per share4.30
Pfizer Inc. stock logo
PFE
Pfizer
$62.46B2.17$4.36 per share5.47$15.62 per share1.53
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$4.09B$10.9626.5013.572.6217.39%176.11%12.39%8/5/2025 (Estimated)
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$480M$4.7522.7313.290.7020.76%51.93%17.40%8/6/2025 (Estimated)
GSK PLC Sponsored ADR stock logo
GSK
GSK
$3.29B$1.9419.778.221.359.89%48.82%11.15%7/30/2025 (Estimated)
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$274.48M-$3.59N/AN/AN/AN/A-29.28%-27.68%8/5/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$12.2962.0624.411.1522.67%85.51%15.74%8/7/2025 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$17.12B$6.8711.507.960.8227.27%43.23%17.11%7/29/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.3817.307.870.8712.62%20.33%8.53%7/29/2025 (Estimated)

Latest IDYA, LLY, PFE, AMGN, GILD, MRK, and GSK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2025Q1 2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$0.75-$0.82-$0.07-$0.82$2.10 millionN/A
5/1/2025Q1 2025
Amgen Inc. stock logo
AMGN
Amgen
$4.18$4.90+$0.72$3.20$8.05 billion$8.15 billion
5/1/2025Q1 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$4.64$3.34-$1.30$3.06$12.77 billion$12.73 billion
4/30/2025Q1 2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.08$1.13+$0.05$1.00$7.52 billion$10.06 billion
4/29/2025Q1 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.67$0.92+$0.25$0.52$14.43 billion$13.72 billion
4/24/2025Q1 2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$1.77$1.81+$0.04$1.04$6.77 billion$6.67 billion
4/24/2025Q1 2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.16$2.22+$0.06$2.01$15.59 billion$15.53 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$9.523.28%N/A86.86%14 Years
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.162.93%N/A66.53%10 Years
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.694.42%N/A87.11%N/A
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.79%N/A48.82%11 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.244.11%N/A47.16%14 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.727.21%N/A124.64%16 Years

Latest IDYA, LLY, PFE, AMGN, GILD, MRK, and GSK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/2/2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.42164.1%5/16/20255/16/20257/10/2025
5/27/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.814.18%6/16/20256/16/20257/8/2025
4/22/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
quarterly$0.793%6/13/20256/13/20256/27/2025
4/23/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.69%5/9/20255/9/20256/13/2025
5/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.500.73%5/16/20255/16/20256/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
8.70
1.17
0.88
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.16
1.37
1.23
GSK PLC Sponsored ADR stock logo
GSK
GSK
1.21
0.87
0.58
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
N/A
13.92
13.92
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.18
1.37
1.06
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.69
1.41
1.16
Pfizer Inc. stock logo
PFE
Pfizer
0.64
1.26
0.96

Institutional Ownership

CompanyInstitutional Ownership
Amgen Inc. stock logo
AMGN
Amgen
76.50%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%
GSK PLC Sponsored ADR stock logo
GSK
GSK
15.74%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
98.29%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Amgen Inc. stock logo
AMGN
Amgen
0.76%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.27%
GSK PLC Sponsored ADR stock logo
GSK
GSK
10.00%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
2.50%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.13%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
28,000537.71 million533.62 millionOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,6001.24 billion1.24 billionOptionable
GSK PLC Sponsored ADR stock logo
GSK
GSK
68,6292.05 billion1.84 billionOptionable
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
8087.58 million85.39 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
47,000947.74 million946.50 millionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.51 billion2.51 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
81,0005.69 billion5.68 billionOptionable

Recent News About These Companies

Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
Pfizer: An Offensive Play For A Bear Market
Pfizer: An Offensive Play For A Bear Market
Pfizer Inc. stock logo
Pfizer Inc. (NYSE:PFE) Shares Sold by Clarius Group LLC

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Amgen stock logo

Amgen NASDAQ:AMGN

$291.90 +2.28 (+0.79%)
As of 01:19 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Gilead Sciences stock logo

Gilead Sciences NASDAQ:GILD

$109.23 +1.23 (+1.14%)
As of 01:19 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

GSK stock logo

GSK NYSE:GSK

$37.92 -0.72 (-1.87%)
As of 01:19 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

IDEAYA Biosciences stock logo

IDEAYA Biosciences NASDAQ:IDYA

$21.62 -0.24 (-1.08%)
As of 01:18 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$764.87 -20.16 (-2.57%)
As of 01:19 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$79.57 +0.28 (+0.35%)
As of 01:19 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer stock logo

Pfizer NYSE:PFE

$23.90 +0.03 (+0.10%)
As of 01:19 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.